Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GSKNYSE:MRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGSKGSK$41.30+1.1%$37.66$31.72▼$44.67$84.65B0.524.82 million shs5.09 million shsMRKMerck & Co., Inc.$81.32+2.5%$78.98$73.31▼$134.63$204.20B0.3812.76 million shs13.24 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGSKGSK-0.88%-1.85%+11.54%+3.51%-0.86%MRKMerck & Co., Inc.+0.44%+4.04%+4.51%-16.22%-39.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGSKGSK1.8796 of 5 stars1.14.02.50.02.70.01.9MRKMerck & Co., Inc.4.9947 of 5 stars3.23.05.03.93.52.53.8Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGSKGSK 2.27Hold$37.38-9.50% DownsideMRKMerck & Co., Inc. 2.43Hold$109.1934.27% UpsideCurrent Analyst Ratings BreakdownLatest MRK and GSK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025GSKGSKBerenberg BankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold5/20/2025MRKMerck & Co., Inc.Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Cautious5/14/2025MRKMerck & Co., Inc.CitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$115.00 ➝ $84.004/28/2025GSKGSKHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell4/22/2025MRKMerck & Co., Inc.Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$85.004/17/2025MRKMerck & Co., Inc.GuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$115.00 ➝ $115.004/15/2025GSKGSKBNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$35.25(Data available from 6/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGSKGSK$31.53B2.68$6.53 per share6.32$8.07 per share5.12MRKMerck & Co., Inc.$63.92B3.19$2.82 per share28.82$14.85 per share5.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGSKGSK$3.29B$1.9425.978.881.128.13%48.59%11.11%7/30/2025 (Estimated)MRKMerck & Co., Inc.$17.12B$6.8712.088.210.7726.67%45.35%17.36%7/29/2025 (Estimated)Latest MRK and GSK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/30/2025Q1 2025GSKGSK$1.08$1.13+$0.05$1.00$7.52 billion$10.06 billion4/24/2025Q1 2025MRKMerck & Co., Inc.$2.16$2.22+$0.06$2.01$15.59 billion$15.53 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGSKGSK$1.684.07%N/A86.60%N/AMRKMerck & Co., Inc.$3.243.98%N/A47.16%14 YearsLatest MRK and GSK DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025GSKGSKquarterly$0.42164.1%5/16/20255/16/20257/10/20255/27/2025MRKMerck & Co., Inc.quarterly$0.814.18%6/16/20256/16/20257/8/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGSKGSK1.120.780.52MRKMerck & Co., Inc.0.791.361.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGSKGSK15.74%MRKMerck & Co., Inc.76.07%Insider OwnershipCompanyInsider OwnershipGSKGSK10.00%MRKMerck & Co., Inc.0.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGSKGSK90,1002.05 billion1.87 billionOptionableMRKMerck & Co., Inc.69,0002.51 billion2.53 billionOptionableMRK and GSK HeadlinesRecent News About These CompaniesMerck & Co., Inc. (NYSE:MRK) Trading Up 1.8% - Here's What HappenedJune 10 at 2:15 PM | marketbeat.comDrug pricing reform talks with US government lack clarity, industry executives sayJune 10 at 2:03 PM | reuters.comMerck & Co., Inc. (MRK) Presents at Goldman Sachs 46th Annual Global Healthcare Conference TranscriptJune 10 at 1:17 PM | seekingalpha.comMerck Secures FDA Nod for New RSV Antibody Enflonsia in InfantsJune 10 at 11:51 AM | zacks.comRFK Jr.'s firing of CDC vaccine advisors 'circumvents science' and could threaten public health, experts sayJune 10 at 11:50 AM | cnbc.comWill Merck's Keytruda Continue to Drive Growth Amid Looming LOE?June 10 at 10:50 AM | zacks.comMerck's Cholesterol Lowering Drug Hits Primary Goal In Two Pivotal TrialsJune 10 at 10:47 AM | finance.yahoo.comCantor Fitzgerald Estimates MRK FY2026 EarningsJune 10 at 8:56 AM | marketbeat.comMerck & Co., Inc. (NYSE:MRK) Shares Acquired by Sarasin & Partners LLPJune 10 at 8:55 AM | marketbeat.comHandelsbanken Fonder AB Cuts Stake in Merck & Co., Inc. (NYSE:MRK)June 10 at 8:28 AM | marketbeat.comAvanza Fonder AB Has $20.30 Million Position in Merck & Co., Inc. (NYSE:MRK)June 10 at 7:38 AM | marketbeat.comMerck & Co., Inc. (NYSE:MRK) Shares Sold by Abacus FCF Advisors LLCJune 10 at 7:37 AM | marketbeat.comFirst National Bank of Mount Dora Trust Investment Services Lowers Position in Merck & Co., Inc. (NYSE:MRK)June 10 at 7:28 AM | marketbeat.comLivforsakringsbolaget Skandia Omsesidigt Cuts Position in Merck & Co., Inc. (NYSE:MRK)June 10 at 7:06 AM | marketbeat.comSimplicity Wealth LLC Increases Holdings in Merck & Co., Inc. (NYSE:MRK)June 10 at 6:48 AM | marketbeat.comCardinal Capital Management Inc. Boosts Stock Position in Merck & Co., Inc. (NYSE:MRK)June 10 at 6:11 AM | marketbeat.comMerck & Co., Inc. (NYSE:MRK) Shares Sold by Yousif Capital Management LLCJune 10 at 6:11 AM | marketbeat.comFarther Finance Advisors LLC Raises Stake in Merck & Co., Inc. (NYSE:MRK)June 10 at 5:51 AM | marketbeat.comJune 9 at 4:52 PM | gurufocus.comFDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstaZenecaJune 9 at 3:30 PM | cnbc.comUS FDA approves Merck's RSV antibody for infantsJune 9 at 3:16 PM | reuters.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRK and GSK Company DescriptionsGSK NYSE:GSK$41.30 +0.44 (+1.07%) Closing price 03:59 PM EasternExtended Trading$41.32 +0.03 (+0.06%) As of 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.Merck & Co., Inc. NYSE:MRK$81.32 +1.99 (+2.51%) Closing price 03:59 PM EasternExtended Trading$81.59 +0.27 (+0.33%) As of 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Stock Hits All-Time Highs: Smart Buy or FOMO Trap? These 3 Stocks Could Be Back in Play Before You Know It Qualcomm: What Monday’s Jump Tells Us About the Stock's Prospects Government Mandate Sends eVTOL Stocks Flying Meta Pulls Ahead of the Mag 7: Analysts Predict a Breakout Year ASML’s AI Edge: How Its EUV Tech Is Creating a New Monopoly Robinhood Drops on S&P Snub—Is a Bigger Pullback Coming? 3 Tightly-Held Growth Stocks Set Up for Short Squeezes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
